Search research articles
Contact Us
Filters
Showing results (41-50 of 787) with videos related to
Page
of 79
Sort By:
Nature Reviews. Clinical Oncology
|
October 15, 2014
Decade in review-haematological cancer: advances in biology and therapy
S Vincent Rajkumar, Philippe Moreau
Blood Reviews
|
June 14, 2008
Frontline treatment of multiple myeloma in elderly patients
Philippe Moreau, Cyrille Hulin, Thierry Facon
Blood
|
April 4, 2015
Frontline therapy of multiple myeloma
Philippe Moreau, Michel Attal, Thierry Facon
Expert Review of Anticancer Therapy
|
October 14, 2020
Monoclonal antibodies as an addition to current myeloma therapy strategies
Maxime Jullien, Cyrille Touzeau, Philippe Moreau
Hematology/Oncology Clinics of North America
|
September 13, 2014
Frontline Therapy for Patients with Multiple Myeloma not Eligible for Stem Cell Transplantation
Philippe Moreau, Cyrille Hulin, Thierry Facon
Oncotargets and Therapy
|
August 15, 2019
Update on elotuzumab for the treatment of relapsed/refractory multiple myeloma: patients' selection and perspective
Sabrina Trudel, Philippe Moreau, Cyrille Touzeau
Biologics : Targets & Therapy
|
January 19, 2026
Teclistamab for Relapsed or Refractory Multiple Myeloma: A Review of Efficacy, Safety, Resistance Mechanisms and Future Directions
Bénédicte Piron, Philippe Moreau, Cyrille Touzeau
Future Oncology (London, England)
|
December 8, 2020
Carfilzomib in combination with daratumumab in the management of relapsed multiple myeloma
Cyrille Touzeau, Chloé Antier, Philippe Moreau
The New England Journal of Medicine
|
July 6, 2017
Drug Combinations with Transplantation for Myeloma
Michel Attal, Paul G Richardson, Philippe Moreau
Expert Review of Clinical Immunology
|
July 5, 2016
The role of SLAMF7 in multiple myeloma: impact on therapy
Jean-Samuel Boudreault, Cyrille Touzeau, Philippe Moreau
Page
of 79
Search research articles
Search
Showing results (41-50 of 787) with videos related to
Sort By:
Page
of 79
Nature Reviews. Clinical Oncology
|
October 15, 2014
Decade in review-haematological cancer: advances in biology and therapy
S Vincent Rajkumar, Philippe Moreau
Blood Reviews
|
June 14, 2008
Frontline treatment of multiple myeloma in elderly patients
Philippe Moreau, Cyrille Hulin, Thierry Facon
Blood
|
April 4, 2015
Frontline therapy of multiple myeloma
Philippe Moreau, Michel Attal, Thierry Facon
Expert Review of Anticancer Therapy
|
October 14, 2020
Monoclonal antibodies as an addition to current myeloma therapy strategies
Maxime Jullien, Cyrille Touzeau, Philippe Moreau
Hematology/Oncology Clinics of North America
|
September 13, 2014
Frontline Therapy for Patients with Multiple Myeloma not Eligible for Stem Cell Transplantation
Philippe Moreau, Cyrille Hulin, Thierry Facon
Oncotargets and Therapy
|
August 15, 2019
Update on elotuzumab for the treatment of relapsed/refractory multiple myeloma: patients' selection and perspective
Sabrina Trudel, Philippe Moreau, Cyrille Touzeau
Biologics : Targets & Therapy
|
January 19, 2026
Teclistamab for Relapsed or Refractory Multiple Myeloma: A Review of Efficacy, Safety, Resistance Mechanisms and Future Directions
Bénédicte Piron, Philippe Moreau, Cyrille Touzeau
Future Oncology (London, England)
|
December 8, 2020
Carfilzomib in combination with daratumumab in the management of relapsed multiple myeloma
Cyrille Touzeau, Chloé Antier, Philippe Moreau
The New England Journal of Medicine
|
July 6, 2017
Drug Combinations with Transplantation for Myeloma
Michel Attal, Paul G Richardson, Philippe Moreau
Expert Review of Clinical Immunology
|
July 5, 2016
The role of SLAMF7 in multiple myeloma: impact on therapy
Jean-Samuel Boudreault, Cyrille Touzeau, Philippe Moreau
Page
of 79